Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 11.09 is in line with its 5-year average of 11.89, near the low end of its 5-year range (1.91–41.98).
As of the fiscal period ended Tuesday, June 30, 2026. 22.48% above its 12-month average of 9.06.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.09.
QUICK RATIO (ACID-TEST)
11.09
QUICK RATIO (ACID-TEST) AVG TTM
9.06
QUICK RATIO (ACID-TEST) AVG 3Y
9.96
QUICK RATIO (ACID-TEST) AVG 5Y
11.89
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.48%
CURRENT VS 3Y AVG
+11.40%
CURRENT VS 5Y AVG
-6.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
+270.95%
vs the sector median at left
Alpha Tau Medical Ltd
Market Cap
$1.36B
Quick Ratio (Acid-Test)
11.09
TTM Avg
9.06
3Y Avg
9.96
5Y Avg
11.89
Market Cap
$1.33B
Quick Ratio (Acid-Test)
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
Market Cap
$1.40B
Quick Ratio (Acid-Test)
5.07
TTM Avg
3.94
3Y Avg
5.82
5Y Avg
6.31
Market Cap
$1.38B
Quick Ratio (Acid-Test)
35.85
TTM Avg
18.03
3Y Avg
18.03
5Y Avg
18.03
Market Cap
$1.43B
Quick Ratio (Acid-Test)
5.61
TTM Avg
9.29
3Y Avg
11.65
5Y Avg
16.84
Market Cap
$1.40B
Quick Ratio (Acid-Test)
11.11
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$1.24B
Quick Ratio (Acid-Test)
19.73
TTM Avg
13.53
3Y Avg
9.78
5Y Avg
15.63
Market Cap
$1.47B
Quick Ratio (Acid-Test)
2.94
TTM Avg
3.04
3Y Avg
2.84
5Y Avg
2.90
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.36B | 11.09 | 9.06 | 9.96 | 11.89 |
| Kardigan, Inc. (KARD)vs › | $1.29B | 8.72 | 9.20 | 9.20 | 9.20 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 14.16 | 12.98 | 15.39 | 17.04 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | 5.07 | 3.94 | 5.82 | 6.31 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | 35.85 | 18.03 | 18.03 | 18.03 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 5.61 | 9.29 | 11.65 | 16.84 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 11.11 | 12.01 | 12.01 | 12.01 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | 19.73 | 13.53 | 9.78 | 15.63 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 2.94 | 3.04 | 2.84 | 2.90 |
| Innovage Holding Corp. (INNV)vs › | $1.23B | 1.05 | 1.06 | 1.16 | 1.68 |
Quick Ratio
11.09
Excludes inventory
Current Ratio
11.09
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 11.09 |
| 2026-03-31 | 7.79 |
| 2025-12-31 | 7.45 |
| 2025-09-30 | 8.43 |
| 2025-06-30 | 10.52 |
| 2025-03-31 | 5.81 |
| 2024-12-31 | 7.40 |
| 2024-09-30 | 10.99 |
| 2024-06-30 | 11.66 |
| 2024-03-31 | 11.60 |
| 2023-12-31 | 12.07 |
| 2023-09-30 | 14.66 |
| 2023-06-30 | 17.74 |
| 2023-03-31 | 18.90 |
| 2022-12-31 | 24.55 |
| 2022-09-30 | 33.20 |
| 2022-06-30 | 41.98 |
| 2022-03-31 | 17.66 |
| 2021-12-31 | 7.41 |
| 2021-09-30 | 1.91 |
| 2021-06-30 | 18.21 |
| 2021-03-31 | 10.20 |
| 2020-12-31 | 22.73 |
| 2020-09-30 | 22.73 |
| 2020-06-30 | 22.73 |
| 2020-03-31 | 53.89 |
| 2019-12-31 | 22.11 |
| 2019-09-30 | 22.11 |
| 2019-06-30 | 22.11 |
| 2019-03-31 | 22.11 |
